{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011077","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.699552+00:00","generated_at":"2026-06-04T08:28:15.546700+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Matinas BioPharma oral LNC-docetaxel shows no toxicity in mouse study; 8x higher dose tolerated without weight loss","bullets":["Total docetaxel delivered orally via LNC was >8x IV dose by Day 22; all IV mice lost avg 20% weight, LNC mice maintained weight normal.","One IV-docetaxel mouse died (32% weight loss); LNC-docetaxel mice had no mortality and weight statistically same as saline controls.","Daily oral LNC-docetaxel dose 50% higher and total drug 3.5x greater than prior study that showed comparable anti-tumor activity to IV-docetaxel.","Company plans further evaluation of higher doses in additional tumors and other toxic chemotherapies using LNC platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011077","json":"https://secwatch.observer/filing/0001493152-24-011077.json","markdown":"https://secwatch.observer/filing/0001493152-24-011077.md","text":"https://secwatch.observer/filing/0001493152-24-011077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224011077/0001493152-24-011077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224011077/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:28:15.546700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}